# Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

> **NCT02149108** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 768 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Nintedanib (BIBF 1120)
- **DRUG:** Placebo
- **DRUG:** BSC
- **DRUG:** BSC

## Key facts

- **NCT ID:** NCT02149108
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-25
- **Primary completion:** 2016-05-13
- **Final completion:** 2016-08-25
- **Target enrollment:** 768 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149108, "Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02149108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*